{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:50:35Z","timestamp":1762660235924,"version":"3.40.5"},"reference-count":53,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDS"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>COVID-19 and tuberculosis (TB) are infectious diseases that predominantly\naffect the respiratory system with common symptoms, such as cough, fever, and shortness\nof breath, making them dual burdens.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>This review will discuss the characteristics of the coexistence of TB and new infectious\nillnesses to provide a framework for addressing the current epidemic. Currently, there are no clear\nand significant data on COVID-19 infection in TB patients, they may not respond appropriately to\ndrug therapy and may have worse treatment outcomes, especially if their TB treatment is interrupted.\nDue to emergence, measurements should be taken to minimize TB and COVID-19 transmission\nin communal settings and health care institutions were created. For both TB and COVID-19, accurate\ndiagnostic testing and well-designed, and established therapeutic strategies are required for effective\ntreatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Several health care organizations and networks have specimen transit methods that can be\nutilized to diagnose and monitor the etiology and progression of COVID 19 and perform contact tracing\nin developed and underdeveloped nations. Furthermore, patients and health care programs could\nbenefit from increased use of digital health technology, which could improve communication, counseling,\ntreatment, and information management, along with other capabilities to improve health care.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions:<\/jats:title>\n<jats:p>Patients with COVID-19 pulmonary\/respiratory problems may seek treatment from\nrespiratory physicians, pulmonologists, TB experts, and even primary health care workers. To have\nprophylactic and therapeutic strategies against COVID-19, TB patients should take the appropriate\nhealth care measures recommended by health care professionals\/government officials and maintain\ntheir TB therapy as indicated.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1574886317666220518092819","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T10:42:15Z","timestamp":1653043335000},"page":"276-283","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Critical Clinical Evaluation of COVID-19 Patients with Tuberculosis in the\nIndian Sub-Continent"],"prefix":"10.2174","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6698-8179","authenticated-orcid":true,"given":"Hemalatha","family":"Selvaraj","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Nandha College of Pharmacy, Tamilnadu, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumudha","family":"Damadarosamy","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical\nChemistry, Karpagam Academy of Higher Education, Tamil Nadu, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natarajan","family":"Kiruthiga","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Nandha College of Pharmacy, Tamilnadu, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.Reeta Vijaya","family":"Rani","sequence":"additional","affiliation":[{"name":"Surya School of Pharmacy, Surya Group of Institutions, Tamil Nadu, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanagaraj","family":"Duraisamy","sequence":"additional","affiliation":[{"name":"Deputy Director of Medical Services, District\nTB Centre, Erode, Tamil Nadu, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muralikrishnan","family":"Dhanasekaran","sequence":"additional","affiliation":[{"name":"Department of Drug Discovery Development, Harrison College of Pharmacy, Auburn University, Auburn, Alabama, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Deruiter","sequence":"additional","affiliation":[{"name":"Department of Drug Discovery Development, Harrison College of Pharmacy, Auburn University, Auburn, Alabama, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai 200032, China"},{"name":"Department of Laboratory\nMedicine and Pathology, University of Washington, Seattle, WA 98195, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sivakumar","family":"Thangavel","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Nandha College of Pharmacy, Tamilnadu, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Parise","sequence":"additional","affiliation":[{"name":"Department of Drug Discovery Development, Harrison College of Pharmacy, Auburn University, Auburn, Alabama, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S2213-2600(21)00218-6","volume":"9","author":"Osuchowski M.F.","year":"2021","unstructured":"Osuchowski M.F.; Winkler M.S.; Skirecki T.; The COVID-19 puzzle: Deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir Med 2021,9(6),622-642","journal-title":"Lancet Respir Med"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"e0250708","DOI":"10.1371\/journal.pone.0250708","volume":"16","author":"Peiris S.","year":"2021","unstructured":"Peiris S.; Mesa H.; Aysola A.; Pathological findings in organs and tissues of patients with COVID-19: A systematic review. PLoS One 2021,16(4),e0250708","journal-title":"PLoS One"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"Lu R.","year":"2020","unstructured":"Lu R.; Zhao X.; Li J.; Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 2020,395(10224),565-574","journal-title":"Lancet"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","volume":"5","author":"Group C.S.","year":"2020","unstructured":"Group C.S.; The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020,5(4),536-544","journal-title":"Nat Microbiol"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"Hoffmann M.","year":"2020","unstructured":"Hoffmann M.; Kleine-Weber H.; Schroeder S.; SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020,181(2),271-280","journal-title":"Cell"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.bbrc.2020.02.071","volume":"525","author":"Chen Y.","year":"2020","unstructured":"Chen Y.; Guo Y.; Pan Y.; Zhao Z.J.; Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun 2020,525(1),135-140","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-79139-8","volume":"11","author":"Piplani S.","year":"2021","unstructured":"Piplani S.; Singh P.K.; Winkler D.A.; Petrovsky N.; In silico comparison of SARS-CoV-2 spike protein-ACE2 binding affinities across species and implications for virus origin. Sci Rep 2021,11(1),1-13","journal-title":"Sci Rep"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"104742","DOI":"10.1016\/j.antiviral.2020.104742","volume":"176","author":"Coutard B.","year":"2020","unstructured":"Coutard B.; Valle C.; de Lamballerie X.; Canard B.; Seidah N.G.; Decroly E.; The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res 2020,176,104742","journal-title":"Antiviral Res"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1161\/CIRCRESAHA.121.318902","volume":"128","author":"Lei Y.","year":"2021","unstructured":"Lei Y.; Zhang J.; Schiavon C.R.; SARS-CoV-2 spike protein impairs endothelial function via downregulation of ACE 2. Circ Res 2021,128(9),1323-1326","journal-title":"Circ Res"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3390\/vaccines9010036","volume":"9","author":"Suzuki Y.J.","year":"2021","unstructured":"Suzuki Y.J.; Gychka S.G.; SARS-CoV-2 spike protein elicits cell signaling in human host cells: Implications for possible consequences of COVID-19 vaccines. Vaccines 2021,9(1),36","journal-title":"Vaccines"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/S1473-3099(21)00262-0","volume":"21","author":"Ramanathan M.","year":"2021","unstructured":"Ramanathan M.; Ferguson I.D.; Miao W.; Khavari P.A.; SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity. Lancet Infect Dis 2021,21(8),1070","journal-title":"Lancet Infect Dis"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","volume":"183","author":"Moderbacher C.R.","year":"2020","unstructured":"Moderbacher C.R.; Ramirez S.I.; Dan J.M.; Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 2020,183(4),996-1012","journal-title":"Cell"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","volume":"8","author":"Xu Z.","year":"2020","unstructured":"Xu Z.; Shi L.; Wang Y.; Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020,8(4),420-422","journal-title":"Lancet Respir Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1155\/2020\/1401053","author":"Crisan-Dabija R","year":"2020","unstructured":"Crisan-Dabija R; Grigorescu C; Pavel C-A; Tuberculosis and COVID-19: Lessons from the past viral outbreaks and possible future outcomes. Canadian Respiratory Journal 2020,2020","journal-title":"Canadian Respiratory Journal"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"Wang M.","year":"2020","unstructured":"Wang M.; Cao R.; Zhang L.; Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020,30(3),269-271","journal-title":"Cell Res"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1056\/NEJMoa2001191","volume":"382","author":"Holshue M.L.","year":"2020","unstructured":"Holshue M.L.; DeBolt C.; Lindquist S.; First case of 2019 novel coronavirus in the United States. N Engl J Med 2020,382(10),929-936","journal-title":"N Engl J Med"},{"key":"ref=17","author":"Regeneron PR","year":"2022","unstructured":"Regeneron PR;  Regeneron\u2019s casirivimab and imdevimab antibody cocktail for COVID-19 is first combination therapy to receive FDA emergency use authorization 2022","journal-title":"Regeneron\u2019s casirivimab and imdevimab antibody cocktail for COVID-19 is first combination therapy to receive FDA emergency use authorization"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1001\/jama.2020.8630","volume":"323","author":"Rosenberg E.S.","year":"2020","unstructured":"Rosenberg E.S.; Dufort E.M.; Udo T.; Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA 2020,323(24),2493-2502","journal-title":"JAMA"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.pulmoe.2020.07.003","volume":"27","author":"Cortegiani A.","year":"2021","unstructured":"Cortegiani A.; Ippolito M.; Greco M.; Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Pulmonology 2021,27(1),52-66","journal-title":"Pulmonology"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"Mehta P.","year":"2020","unstructured":"Mehta P.; McAuley D.F.; Brown M.; Sanchez E.; Tattersall R.S.; Manson J.J.; COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 2020,395(10229),1033-1034","journal-title":"Lancet"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jinf.2020.04.017","volume":"81","author":"Cantini F.","year":"2020","unstructured":"Cantini F.; Niccoli L.; Matarrese D.; Nicastri E.; Stobbione P.; Goletti D.; Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect 2020,81(2),318-356","journal-title":"J Infect"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.jinf.2020.06.052","volume":"81","author":"Cantini F.","year":"2020","unstructured":"Cantini F.; Niccoli L.; Nannini C.; Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study. J Infect 2020,81(4),647-679","journal-title":"J Infect"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"11475","DOI":"10.1038\/s41598-018-29659-1","volume":"8","author":"Ong C.W.M.","year":"2018","unstructured":"Ong C.W.M.; Fox K.; Ettorre A.; Elkington P.T.; Friedland J.S.; Hypoxia increases neutrophil-driven matrix destruction after exposure to Mycobacterium tuberculosis. Sci Rep 2018,8(1),11475","journal-title":"Sci Rep"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"100683","DOI":"10.1016\/j.eclinm.2020.100683","volume":"31","author":"Raman B.","year":"2021","unstructured":"Raman B.; Cassar M.P.; Tunnicliffe E.M.; Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. EClinicalMedicine 2021,31,100683","journal-title":"EClinicalMedicine"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1093\/infdis\/jiaa578","volume":"222","author":"Falasca L.","year":"2020","unstructured":"Falasca L.; Nardacci R.; Colombo D.; Postmortem findings in Italian patients with COVID-19: A descriptive full autopsy study of cases with and without comorbidities. J Infect Dis 2020,222(11),1807-1815","journal-title":"J Infect Dis"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1055\/s-0040-1715798","volume":"120","author":"Gerotziafas G.T.","year":"2020","unstructured":"Gerotziafas G.T.; Catalano M.; Colgan M.P.; Guidance for the management of patients with vascular disease or cardiovascular risk factors and COVID-19: Position paper from VAS-European independent foundation in angiology\/vascular medicine. Thromb Haemost 2020,120(12),1597-1628","journal-title":"Thromb Haemost"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3947\/ic.2019.51.2.142","volume":"51","author":"Ha H.","year":"2019","unstructured":"Ha H.; Kim K.H.; Park J.H.; Thromboembolism in Mycobacterium tuberculosis infection: Analysis and literature review. Infect Chemother 2019,51(2),142-149","journal-title":"Infect Chemother"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"9333.2009","DOI":"10.1186\/1757-1626-2-9333","volume":"2","author":"Goncalves IM","year":"2009","unstructured":"Goncalves IM; Alves DC; Carvalho A; do Ceu Brito M; Calvario F; Duarte R; Tuberculosis and venous thromboembolism: A case series. Cases J 2009,2,9333.2009","journal-title":"Cases J"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ijtb.2020.02.004","volume":"67","author":"Yasri S.","year":"2020","unstructured":"Yasri S.; Wiwanitkit V.; Tuberculosis and novel Wuhan coronavirus infection: Pathological interrelationship. Indian J Tuberc 2020,67(2),264","journal-title":"Indian J Tuberc"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41577-020-0346-x","volume":"20","author":"Acharya D.","year":"2020","unstructured":"Acharya D.; Liu G.; Gack M.U.; Dysregulation of type I interferon responses in COVID-19. Nat Rev Immunol 2020,20(7),397-398","journal-title":"Nat Rev Immunol"},{"key":"ref=31","doi-asserted-by":"publisher","DOI":"10.1101\/2020.11.25.20236646","author":"Sheerin D.","year":"2020","unstructured":"Sheerin D.; Abhimanyu X.W.; Johnson W.E.; Coussens A.; Systematic evaluation of transcriptomic disease risk and diagnostic biomarker overlap between COVID-19 and tuberculosis: A patient-level meta-analysis. medRxiv 2020","journal-title":"medRxiv"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/imr.12269","volume":"264","author":"Cliff J.M.","year":"2015","unstructured":"Cliff J.M.; Kaufmann S.H.; McShane H.; van Helden P.; O\u2019Garra A.; The human immune response to tuberculosis and its treatment: A view from the blood. Immunol Rev 2015,264(1),88-102","journal-title":"Immunol Rev"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/s41591-020-0968-3","volume":"26","author":"Gupta A.","year":"2020","unstructured":"Gupta A.; Madhavan M.V.; Sehgal K.; Extrapulmonary manifestations of COVID-19. Nat Med 2020,26(7),1017-1032","journal-title":"Nat Med"},{"key":"ref=34","first-page":"356","author":"Masahiro N.C.S.","year":"2017","unstructured":"Masahiro N.C.S.;  The travel and tropical medicine manual Fifth\nEdition 2017,356-370","journal-title":"The travel and tropical medicine manual Fifth\nEdition"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2478\/jtim-2020-0010","volume":"8","author":"Yang H.","year":"2020","unstructured":"Yang H.; Lu S.; COVID-19 and Tuberculosis. J Transl Int Med 2020,8(2),59-65","journal-title":"J Transl Int Med"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/14740338.2016.1240783","volume":"15","author":"Minozzi S","year":"2016","unstructured":"Minozzi S; Bonovas S; Lytras T; Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: A systematic review and meta-analysis. Exp Opin Drug Saf 2016,15(sup1),11-34","journal-title":"Exp Opin Drug Saf"},{"author":"Nanzip B.N.","key":"ref=37","unstructured":"Nanzip B.N.;  Extrapulmonary Tuberculosis (EPTB) Symptoms, Types, Diagnosis, and Treatment, Jotscroll 2020. Available from:  (Accessed on 13 Apr 2022)"},{"key":"ref=38","unstructured":"Revised National Tuberculosis Control Programme. Annual status report 2019 Central TB Division, Ministry of Health and Family Welfare, Govt of India, New Delhi, India: RNTCP."},{"author":"Hopkins J.","key":"ref=39","unstructured":"Hopkins J.;  University of Medicine. Coronavirus Resource Center.COVID-19 dashboard by the center for Systems Science and Engineering CSSE at Johns Hopkins. 2020. Available from: (Accessed on 13 Apr 2022)."},{"first-page":"73","year":"2020","key":"ref=40","unstructured":"WHO. Coronavirus disease 2019 (COVID-19): Situation report. 2020,73"},{"year":"2020","author":"Book W.","key":"ref=41","unstructured":"Book W.; WHO operational handbook on tuberculosis: Module 1:\nPrevention: Tuberculosis preventive treatment. 2020"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"2000547","DOI":"10.1183\/13993003.00547-2020","volume":"55","author":"Guan W.J.","year":"2020","unstructured":"Guan W.J.; Liang W.H.; Zhao Y.; Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis. Eur Respir J 2020,55(5),2000547","journal-title":"Eur Respir J"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S0140-6736(18)30484-7","volume":"391","author":"Wingfield T.","year":"2018","unstructured":"Wingfield T.; Tovar M.A.; Datta S.; Saunders M.J.; Evans C.A.; Addressing social determinants to end tuberculosis. Lancet 2018,391(10126),1129-1132","journal-title":"Lancet"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"2002105","DOI":"10.1183\/13993003.02105-2020","volume":"56","author":"Khurana A.K.","year":"2020","unstructured":"Khurana A.K.; Aggarwal D.; The (in) significance of TB and COVID-19 co-infection. Eur Respir J 2020,56(2),2002105","journal-title":"Eur Respir J"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40001-020-00456-9","volume":"25","author":"Meo S.A.","year":"2020","unstructured":"Meo S.A.; Abukhalaf A.A.; Alomar A.A.; AlMutairi F.J.; Usmani A.M.; Klonoff D.C.; Impact of lockdown on COVID-19 prevalence and mortality during 2020 pandemic: Observational analysis of 27 countries. Eur J Med Res 2020,25(1),56","journal-title":"Eur J Med Res"},{"author":"Indianexpress N.","key":"ref=46","unstructured":"Indianexpress N.;"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.3201\/eid2611.203163","volume":"26","author":"Migliori G.B.","year":"2020","unstructured":"Migliori G.B.; Thong P.M.; Akkerman O.; Worldwide effects of coronavirus disease pandemic on tuberculosis services, January-April 2020. Emerg Infect Dis 2020,26(11),2709-2712","journal-title":"Emerg Infect Dis"},{"key":"ref=48","author":"Liu D","year":"2021","unstructured":"Liu D; Shameem M.;  Future Science 2021","journal-title":"Future Science"},{"key":"ref=49","author":"India T.","year":"2014","unstructured":"India T.;  Revised national tuberculosis control programme annual status report central TB division, directorate general of health services, ministry of health and family welfare 2014","journal-title":"Revised national tuberculosis control programme annual status report central TB division, directorate general of health services, ministry of health and family welfare"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"2001708","DOI":"10.1183\/13993003.01708-2020","volume":"56","author":"Stochino C.","year":"2020","unstructured":"Stochino C.; Villa S.; Zucchi P.; Parravicini P.; Gori A.; Raviglione M.C.; Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital. Eur Respir J 2020,56(1),2001708","journal-title":"Eur Respir J"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1080\/23744235.2020.1806353","volume":"52","author":"Sy K.T.L.","year":"2020","unstructured":"Sy K.T.L.; Haw N.J.L.; Uy J.; Previous and active tuberculosis increases risk of death and prolongs recovery in patients with COVID-19. Infect Dis (Lond) 2020,52(12),902-907","journal-title":"Infect Dis (Lond)"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"e2005","DOI":"10.1093\/cid\/ciaa1198","volume":"73","year":"2021","unstructured":"Risk Factors for Coronavirus Disease 2019 (COVID-19). Death in a Population Cohort Study from the Western Cape Province, South Africa. Clin Infect Dis 2021,73(7),e2005-e2015","journal-title":"Clin Infect Dis"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"78","DOI":"10.5588\/ijtld.20.0786","volume":"25","author":"Casco N.","year":"2021","unstructured":"Casco N.; Jorge A.L.; Palmero D.; TB and COVID-19 coinfection: Rationale and aims of a global study. Int J Tuberc Lung Dis 2021,25(1),78-80","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["Current Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574886317666220518092819","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/204952\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574886317666220518092819","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,6]],"date-time":"2023-08-06T15:05:46Z","timestamp":1691334346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/204952\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574886317666220518092819","relation":{},"ISSN":["1574-8863"],"issn-type":[{"type":"print","value":"1574-8863"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-01-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-22","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}